Search

Your search keyword '"Zanfardino, Mario"' showing total 33 results
Start Over Author "Zanfardino, Mario"
33 results on '"Zanfardino, Mario"'

8. Unsupervised Machine Learning for Risk Stratification and Identification of Relevant Subgroups of Ascending Aorta Dimensions Using Cardiac CT and Clinical Data

Author

Zanfardino, Mario, primary, Punzo, Bruna, additional, Maffei, Erica, additional, Saba, Luca, additional, Bossone, Eduardo, additional, Nistri, Stefano, additional, La Grutta, Ludovico, additional, Franzese, Monica, additional, Cavaliere, Carlo, additional, and Cademartiri, Filippo, additional

Published
2023
Full Text
View/download PDF

11. Machine learning improves the accuracy of graft weight prediction in living donor liver transplantation

Author

Giglio, Mariano Cesare, primary, Zanfardino, Mario, additional, Franzese, Monica, additional, Zakaria, Hazem, additional, Alobthani, Salah, additional, Zidan, Ahmed, additional, Ayoub, Islam Ismail, additional, Shoreem, Hany Abdelmeguid, additional, Lee, Boram, additional, Han, Ho‐Seong, additional, Penna, Andrea Della, additional, Nadalin, Silvio, additional, Troisi, Roberto Ivan, additional, and Broering, Dieter Clemens, additional

Published
2023
Full Text
View/download PDF

15. TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power

Author

Fancello, Laura, primary, Guida, Alessandro, additional, Frige, Gianmaria, additional, Ceol, Arnaud Gerard Michel, additional, Babini, Gabriele, additional, Scaglione, Giovanni Luca, additional, Zanfardino, Mario, additional, Mazza, Tommaso, additional, Ferrando, Lorenzo, additional, Pelicci, Pier Giuseppe, additional, and Mazzarella, Luca, additional

Published
2021
Full Text
View/download PDF

19. miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

Author

Palma, Francesco, primary, Affinito, Alessandra, additional, Nuzzo, Silvia, additional, Roscigno, Giuseppina, additional, Scognamiglio, Iolanda, additional, Ingenito, Francesco, additional, Martinez, Lola, additional, Franzese, Monica, additional, Zanfardino, Mario, additional, Soricelli, Andrea, additional, Fiorelli, Alfonso, additional, Condorelli, Gerolama, additional, and Quintavalle, Cristina, additional

Published
2020
Full Text
View/download PDF

20. Early targeted DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in different stages of impaired glucose homeostasis Cardiovascular Diabetology

Author

Benincasa, Giuditta, primary, Franzese, Monica, additional, Schiano, Concetta, additional, Marfella, Raffaele, additional, Miceli, Marco, additional, Infante, Teresa, additional, Mura, Nunzia Della, additional, Luongo, Marco, additional, Sardu, Celestino, additional, Zanfardino, Mario, additional, Affinito, Ornella, additional, Mansueto, Gelsomina, additional, Sommese, Linda, additional, Nicoletti, Giovanni Francesco, additional, Salvatore, Marco, additional, Paolisso, Giuseppe, additional, and Napoli, Claudio, additional

Published
2020
Full Text
View/download PDF

21. TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power.

Author

Fancello, Laura, Guida, Alessandro, Frige, Gianmaria, Ceol, Arnaud Gerard Michel, Babini, Gabriele, Scaglione, Giovanni Luca, Zanfardino, Mario, Mazza, Tommaso, Ferrando, Lorenzo, Pelicci, Pier Giuseppe, and Mazzarella, Luca

Subjects
GENE regulatory networks, GENE targeting, MEASURING instruments, CANCER patients, STEVEDORES
Abstract

Motivation Tumor mutational burden (TMB) has been proposed as a predictive biomarker for immunotherapy response in cancer patients, as it is thought to enrich for tumors with high neoantigen load. TMB assessed by whole-exome sequencing is considered the gold standard but remains confined to research settings. In the clinical setting, targeted gene panels sampling various genomic sizes along with diverse strategies to estimate TMB were proposed and no real standard has emerged yet. Results We provide the community with TMBleR, a tool to measure the clinical impact of various strategies of panel-based TMB measurement. Availability and implementation R package and docker container (GPL-3 Open Source license): https://acc-bioinfo.github.io/TMBleR/. Graphical-user interface website: https://bioserver.ieo.it/shiny/app/tmbler. Supplementary information Supplementary data are available at Bioinformatics online. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. A DISTRIBUTED ENVIRONMENT FOR HIGH THROUGHPUT SEQUENCING AND OTHER BIOINFORMATIC DATA ANALYSIS

Author

Zanfardino, Mario

Abstract

The fast growth of data produced by modern biomedical studies and the related increasing demand for bioinformatic data processing, make it necessary to optimally use the available hardware and software resources. This growth is such that, despite the fast growth in processor and storage ability, single local computers are unable to keep up with the data and current advances in genome sequencing technology will produce genome-sequence data more quickly than the speed and rate at which processors are getting faster. With the architectures described in the introduction, great progress is being made in biological data processing and today they are commonly used in order to solve computationally intensive problems by sophisticated bioinformatic tools and pipelines, but there is still need for better interfaces able to integrate tools of different origin and to upload processing to remote servers. In this work, a platform has been designed, to integrate applications of different type and to isolates services and databases from one another by providing a middle service layer which has the potential to have significant advantages in the development of bioinformatic data processing system. In particular, an Enterprise service bus architecture has been considered as a possible platform around which a full data processing system might be centred. This type of architecture is intrinsically able to integrate different service resources through a bus-like infrastructure and provides significant features such as lightweight interfacing and easy expansion.

Published
2016

23. DNA methylation profiling of CD04+/CD08+T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study

Author

Benincasa, Giuditta, Franzese, Monica, Schiano, Concetta, Marfella, Raffaele, Miceli, Marco, Infante, Teresa, Sardu, Celestino, Zanfardino, Mario, Affinito, Ornella, Mansueto, Gelsomina, Sommese, Linda, Nicoletti, Giovanni Francesco, Salvatore, Marco, Paolisso, Giuseppe, and Napoli, Claudio

Abstract

DNA methylation can play a pathogenic role in the early stages of hyperglycemia linking homeostasis imbalance and vascular damage.

Published
2020
Full Text
View/download PDF

24. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

Author

Riccio, Eleonora, Zanfardino, Mario, Ferreri, Lucia, Santoro, Ciro, Cocozza, Sirio, Capuano, Ivana, Imbriaco, Massimo, Feriozzi, Sandro, and Pisani, Antonio

Abstract

The treatment options for Fabry disease (FD) are enzyme replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological chaperone migalastat. Since few data are available on the effects of switching from ERT to migalastat, we performed a single-center observational study on seven male Fabry patients (18–66 years) to assess the effects of the switch on renal, cardiac, and neurologic function, health status, pain, lyso-Gb3, a-Gal A activity and adverse effects. Data were retrospectively collected at time of diagnosis of FD (baseline, T0), and after 12 months of ERT (T1), and prospectively after 1 year of therapy with migalastat (T2). No patient died or reported renal, cardiac, or cerebrovascular events during the study period. The predefined measures for cardiac, renal and neurologic function, and FD-related symptoms and questionnaires were stable between baseline and the switch, and remained unchanged with migalastat. However, a significant improvement was observed in left ventricular mass index from baseline to T2 (p?=?0.016), with a significative difference between the treatments (p?=?0.028), and in median proteinuria from T2 vs T1 (p?=?0.048). Moreover, scores of the BPI improved from baseline to T1, and remained stable with migalastat. Plasma lyso-Gb3 levels significantly decreased from baseline to T1 (P?=?0.007) and T2 (P?=?0.003), while did not significantly differ between the two treatments. a-Gal A activity increased from T0 to T2 (p?

Published
2020
Full Text
View/download PDF

25. The complete 12 Mb genome and transcriptome of Nonomuraea gerenzanensis with new insights into its duplicated “magic” RNA polymerase

Author

D’Argenio, Valeria, primary, Petrillo, Mauro, additional, Pasanisi, Daniela, additional, Pagliarulo, Caterina, additional, Colicchio, Roberta, additional, Talà, Adelfia, additional, de Biase, Maria Stella, additional, Zanfardino, Mario, additional, Scolamiero, Emanuela, additional, Pagliuca, Chiara, additional, Gaballo, Antonio, additional, Cicatiello, Annunziata Gaetana, additional, Cantiello, Piergiuseppe, additional, Postiglione, Irene, additional, Naso, Barbara, additional, Boccia, Angelo, additional, Durante, Miriana, additional, Cozzuto, Luca, additional, Salvatore, Paola, additional, Paolella, Giovanni, additional, Salvatore, Francesco, additional, and Alifano, Pietro, additional

Published
2016
Full Text
View/download PDF

28. TCGA-TCIA Impact on Radiogenomics Cancer Research: A Systematic Review.

Author

Zanfardino, Mario, Pane, Katia, Mirabelli, Peppino, Salvatore, Marco, and Franzese, Monica

Subjects
*META-analysis, *CANCER research, *NUCLEOTIDE sequencing, *IMAGING of cancer, *BREAST cancer prognosis
Abstract

In the last decade, the development of radiogenomics research has produced a significant amount of papers describing relations between imaging features and several molecular 'omic signatures arising from next-generation sequencing technology and their potential role in the integrated diagnostic field. The most vulnerable point of many of these studies lies in the poor number of involved patients. In this scenario, a leading role is played by The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA), which make available, respectively, molecular 'omic data and linked imaging data. In this review, we systematically collected and analyzed radiogenomic studies based on TCGA-TCIA data. We organized literature per tumor type and molecular 'omic data in order to discuss salient imaging genomic associations and limitations of each study. Finally, we outlined the potential clinical impact of radiogenomics to improve the accuracy of diagnosis and the prediction of patient outcomes in oncology. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

Author

Eleonora Riccio, Mario Zanfardino, Lucia Ferreri, Ciro Santoro, Sirio Cocozza, Ivana Capuano, Massimo Imbriaco, Sandro Feriozzi, Antonio Pisani, Roberta Esposito, Camilla Russo, Teodolinda Di Risi, Lorenzo Chiariotti, Letizia Spinelli, Andrea Pontillo, Alberto Cuocolo, Gilda Cennamo, Annamria Colao, Riccio, Eleonora, Zanfardino, Mario, Ferreri, Lucia, Santoro, Ciro, Cocozza, Sirio, Capuano, Ivana, Imbriaco, Massimo, and Feriozzi, Sandro

Subjects
Adult, Male, medicine.medical_specialty, 1-Deoxynojirimycin, Adolescent, Drug-Related Side Effects and Adverse Reactions, Urology, Administration, Oral, 030204 cardiovascular system & hematology, Article, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Neurologic function, Migalastat, Genetics research, Genetics, medicine, Humans, Enzyme Replacement Therapy, Adverse effect, Genetics (clinical), 030304 developmental biology, Aged, fabry disease, 0303 health sciences, Proteinuria, business.industry, Treatment options, Enzyme replacement therapy, Drug Tolerance, Middle Aged, medicine.disease, Fabry disease, Real life data, Drug regulation, Recombinant Proteins, Isoenzymes, alpha-Galactosidase, medicine.symptom, business
Abstract

The treatment options for Fabry disease (FD) are enzyme replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological chaperone migalastat. Since few data are available on the effects of switching from ERT to migalastat, we performed a single-center observational study on seven male Fabry patients (18–66 years) to assess the effects of the switch on renal, cardiac, and neurologic function, health status, pain, lyso-Gb3, α-Gal A activity and adverse effects. Data were retrospectively collected at time of diagnosis of FD (baseline, T0), and after 12 months of ERT (T1), and prospectively after 1 year of therapy with migalastat (T2). No patient died or reported renal, cardiac, or cerebrovascular events during the study period. The predefined measures for cardiac, renal and neurologic function, and FD-related symptoms and questionnaires were stable between baseline and the switch, and remained unchanged with migalastat. However, a significant improvement was observed in left ventricular mass index from baseline to T2 (p = 0.016), with a significative difference between the treatments (p = 0.028), and in median proteinuria from T2 vs T1 (p = 0.048). Moreover, scores of the BPI improved from baseline to T1, and remained stable with migalastat. Plasma lyso-Gb3 levels significantly decreased from baseline to T1 (P = 0.007) and T2 (P = 0.003), while did not significantly differ between the two treatments. α-Gal A activity increased from T0 to T2 (p

Published
2020
Full Text
View/download PDF

30. The complete 12 Mb genome and transcriptome of Nonomuraea gerenzanensis with new insights into its duplicated 'magic' RNA polymerase

Author

Pietro Alifano, Adelfia Talà, Daniela Pasanisi, Roberta Colicchio, Antonio Gaballo, Annunziata Gaetana Cicatiello, Miriana Durante, Irene Postiglione, Angelo Boccia, Francesco Salvatore, Paola Salvatore, Giovanni Paolella, Mario Zanfardino, Piergiuseppe Cantiello, Chiara Pagliuca, Luca Cozzuto, Emanuela Scolamiero, Valeria D'Argenio, Maria Stella de Biase, Mauro Petrillo, Caterina Pagliarulo, Barbara Naso, D'Argenio, Valeria, Petrillo, Mauro, Pasanisi, Daniela, Pagliarulo, Caterina, Colicchio, Roberta, Tala', Adelfia, de Biase, Maria Stella, Zanfardino, Mario, Scolamiero, Emanuela, Pagliuca, Chiara, Gaballo, Antonio, Cicatiello, Annunziata Gaetana, Cantiello, Piergiuseppe, Postiglione, Irene, Naso, Barbara, Boccia, Angelo, Durante, Miriana, Cozzuto, Luca, Salvatore, Paola, Paolella, Giovanni, Salvatore, Francesco, Alifano, Pietro, Talà, Adelfia, and Cicatiello, ANNUNZIATA GAETANA

Subjects
0301 basic medicine, Science, Genome, Article, 03 medical and health sciences, chemistry.chemical_compound, Bacterial Proteins, RNA polymerase, Gene duplication, Actinomycetales, polycyclic compounds, Gene, Polymerase, Genetics, Whole genome sequencing, Multidisciplinary, biology, RNA, DNA-Directed RNA Polymerases, Hydrogen-Ion Concentration, biochemical phenomena, metabolism, and nutrition, rpoB, Anti-Bacterial Agents, 030104 developmental biology, chemistry, Mutation, biology.protein, bacteria, Medicine, Teicoplanin, Transcriptome, Actinomycetes, Secondary metabolism, RNA polymerase, Rifampicin-resistance, Genome, Bacterial
Abstract

In contrast to the widely accepted consensus of the existence of a single RNA polymerase in bacteria, several actinomycetes have been recently shown to possess two forms of RNA polymerases due the to co-existence of two rpoB paralogs in their genome. However, the biological significance of the rpoB duplication is obscure. In this study we have determined the genome sequence of the lipoglycopeptide antibiotic A40926 producer Nonomuraea gerenzanensis ATCC 39727, an actinomycete with a large genome and two rpoB genes, i.e. rpoB(S) (the wild-type gene) and rpoB(R) (the mutant-type gene). We next analyzed the transcriptional and metabolite profiles in the wild-type gene and in two derivative strains over-expressing either rpoB(R) or a mutated form of this gene to explore the physiological role and biotechnological potential of the “mutant-type” RNA polymerase. We show that rpoB(R) controls antibiotic production and a wide range of metabolic adaptive behaviors in response to environmental pH. This may give interesting perspectives also with regard to biotechnological applications.

Published
2016

32. The complete 12 Mb genome and transcriptome of Nonomuraea gerenzanensis with new insights into its duplicated "magic" RNA polymerase.

Author

D'Argenio V, Petrillo M, Pasanisi D, Pagliarulo C, Colicchio R, Talà A, de Biase MS, Zanfardino M, Scolamiero E, Pagliuca C, Gaballo A, Cicatiello AG, Cantiello P, Postiglione I, Naso B, Boccia A, Durante M, Cozzuto L, Salvatore P, Paolella G, Salvatore F, and Alifano P

Subjects
Actinomycetales metabolism, Anti-Bacterial Agents biosynthesis, Hydrogen-Ion Concentration, Mutation, Teicoplanin analogs & derivatives, Teicoplanin biosynthesis, Actinomycetales genetics, Bacterial Proteins genetics, DNA-Directed RNA Polymerases genetics, Genome, Bacterial, Transcriptome
Abstract

In contrast to the widely accepted consensus of the existence of a single RNA polymerase in bacteria, several actinomycetes have been recently shown to possess two forms of RNA polymerases due the to co-existence of two rpoB paralogs in their genome. However, the biological significance of the rpoB duplication is obscure. In this study we have determined the genome sequence of the lipoglycopeptide antibiotic A40926 producer Nonomuraea gerenzanensis ATCC 39727, an actinomycete with a large genome and two rpoB genes, i.e. rpoB(S) (the wild-type gene) and rpoB(R) (the mutant-type gene). We next analyzed the transcriptional and metabolite profiles in the wild-type gene and in two derivative strains over-expressing either rpoB(R) or a mutated form of this gene to explore the physiological role and biotechnological potential of the "mutant-type" RNA polymerase. We show that rpoB(R) controls antibiotic production and a wide range of metabolic adaptive behaviors in response to environmental pH. This may give interesting perspectives also with regard to biotechnological applications.

Published
2016
Full Text
View/download PDF

33. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression.

Author

Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Cartenì M, and Morelli F

Subjects
Apoptosis genetics, Blotting, Western, Cell Line, Tumor, DNA Fragmentation drug effects, Down-Regulation drug effects, Gene Expression drug effects, Hep G2 Cells, Humans, In Situ Nick-End Labeling, Neoplasms pathology, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-2 metabolism, Real-Time Polymerase Chain Reaction, bcl-2-Associated X Protein biosynthesis, bcl-2-Associated X Protein genetics, Apoptosis drug effects, Genes, bcl-2 drug effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Neoplasms drug therapy, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Simvastatin pharmacology, bcl-2-Associated X Protein metabolism
Abstract

The statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been proven to be effective in lowering cholesterol and as anti-lipid agents against cardiovascular disease. Recent reports demonstrate an anticancer effect induced by the statins through inhibition of cell proliferation. Probably, these effects are due to suppression of the mevalonate pathway leading to the depletion of various downstream products that play an essential role in cell cycle progression, cell signaling and membrane integrity. To date, although many hypotheses have been proposed, the exact mechanism at the basis of cancer cell growth arrest induced by statins is not known. In this study, we have demonstrated that simvastatin, at a dose of 20 µM for 24-72 h, induced in cancer cells but not in normal cells precise features of apoptosis including increased DNA fragmentation while, at the molecular level simvastatin induced overexpression of the pro-apoptotic gene Bax together with an inhibition of BCL-2, the gene that has the well-known function of protecting cells from apoptosis. The simvastatin-mediated induction of apoptosis in similar cancer cells but not in normal cells is very interesting and may be at the basis of cancer therapy using statins, usually in combination with chemotherapy or to be used as a cancer protective drug. Simvastatin may, thus, play a dual prophylactic role as a lipid-lowering drug for the prevention of heart disease and as an anticancer agent to prevent certain types of cancers.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results